Online Access to Safe and Affordable Medication: Applying human rights law to cyber rule-making and Internet governance
https://www.pharmacychecker.com/
Internet users are benefiting from online access to safe and affordable medications. The pharmaceutical industry views Internet access as a threat and disruptive to its profit model because consumers are paying less than the drug companies intended for them to pay. According to the UN Human Rights Council, access to affordable medication is a human right. As the Internet community seeks to infuse the principles of international human rights law into the discourse and practice of Internet governance it should help maintain the widest possible online access to safe and affordable medication.
https://www.pharmacychecker.com/
Healthcare providers are increasingly breaking the secure supply chain and endangering patients. Learn about counterfeit drugs and most recent incidents involving providers.
Also learn about how you can be a part of the solution by working with the Partnership for Safe Medicines.
In this presentation, Director of National Outreach Shabbir Imber Safdar reviews the current state of counterfeit drugs in America today, discusses some of the myths surrounding importation, and provides tips for saving money safely on the cost of prescription drugs.
The document discusses the dangers American patients face from counterfeit medications obtained outside of the regulated US drug supply chain, such as through fake online Canadian pharmacies. It details how breaks in the secure supply chain, such as patients buying drugs online or some doctors and pharmacists obtaining drugs from unlicensed distributors, can endanger patients by exposing them to counterfeit and unsafe medications. The document aims to dispel myths about obtaining cheaper drugs from outside the US and provides tips for patients to stay safe.
Counterfeit medicines are drugs produced with the intention to deceive that contain incorrect or insufficient active ingredients which can lead to therapeutic failure or drug resistance and sometimes death. Substandard medicines are genuine drugs that do not meet quality specifications due to manufacturing problems and may contain less or more active ingredients than stated. The most frequently counterfeited drugs are expensive medicines like hormones, antibiotics, and anticancer drugs. Globally, 10% of drugs are counterfeit, rising to 25% in developing countries and 50% in some places. Counterfeiting is encouraged by the profitability, weak laws, and large price differences between identical drugs. Actions to address the problems include strong legislation, authentication markings on packages, surveillance, and education.
A presentation by J. Aaron Graham, Executive Director of Brand Safety & Security at Boehringer Ingelheim Pharmaceuticals, Inc., about the threat of imported counterfeit prescription drugs.
This document discusses the threats posed by counterfeit medicines. It provides several examples of counterfeit medicines breaching the US supply chain and being distributed through "Canadian" websites and social media sites. The counterfeits have been found to contain no active ingredients, toxic ingredients, or incorrect doses of active ingredients. They are manufactured under unsafe conditions but can appear virtually indistinguishable from real medicines. The document emphasizes that counterfeit medicines pose a real threat to patient health and safety.
Healthcare providers are increasingly breaking the secure supply chain and endangering patients. Learn about counterfeit drugs and most recent incidents involving providers.
Also learn about how you can be a part of the solution by working with the Partnership for Safe Medicines.
In this presentation, Director of National Outreach Shabbir Imber Safdar reviews the current state of counterfeit drugs in America today, discusses some of the myths surrounding importation, and provides tips for saving money safely on the cost of prescription drugs.
The document discusses the dangers American patients face from counterfeit medications obtained outside of the regulated US drug supply chain, such as through fake online Canadian pharmacies. It details how breaks in the secure supply chain, such as patients buying drugs online or some doctors and pharmacists obtaining drugs from unlicensed distributors, can endanger patients by exposing them to counterfeit and unsafe medications. The document aims to dispel myths about obtaining cheaper drugs from outside the US and provides tips for patients to stay safe.
Counterfeit medicines are drugs produced with the intention to deceive that contain incorrect or insufficient active ingredients which can lead to therapeutic failure or drug resistance and sometimes death. Substandard medicines are genuine drugs that do not meet quality specifications due to manufacturing problems and may contain less or more active ingredients than stated. The most frequently counterfeited drugs are expensive medicines like hormones, antibiotics, and anticancer drugs. Globally, 10% of drugs are counterfeit, rising to 25% in developing countries and 50% in some places. Counterfeiting is encouraged by the profitability, weak laws, and large price differences between identical drugs. Actions to address the problems include strong legislation, authentication markings on packages, surveillance, and education.
A presentation by J. Aaron Graham, Executive Director of Brand Safety & Security at Boehringer Ingelheim Pharmaceuticals, Inc., about the threat of imported counterfeit prescription drugs.
This document discusses the threats posed by counterfeit medicines. It provides several examples of counterfeit medicines breaching the US supply chain and being distributed through "Canadian" websites and social media sites. The counterfeits have been found to contain no active ingredients, toxic ingredients, or incorrect doses of active ingredients. They are manufactured under unsafe conditions but can appear virtually indistinguishable from real medicines. The document emphasizes that counterfeit medicines pose a real threat to patient health and safety.
A presentation by Tom T. Kubic, President and CEO, Pharmaceutical Security Institute and Treasurer, Partnership for Safe Medicines about the threat of imported counterfeit prescription drugs.
Counterfeit drugs: what a doctor should knowMark Davison
Short lecture to medical students on risks, prevalence and detection of fake medicines and protection of patient safety. Essential training for new doctors and pharmacists.
In this webinar I provide an overview of counterfeits in America, I talk about some myths of importation, and I teach patients and patient advocates some great tips for saving money safely.
Securing the Global Pharmaceutical Supply Chain against the Threat of Counter...Yasmin AbdelAziz
In 2012, counterfeit versions of the cancer drug
Avastin were found in 19 American treatment
centers. The impostor drug lacked the active
ingredient, rendering it virtually useless for
treatment purposes.
This document discusses Maine's experience with LD 171, a law passed in 2013 to legalize the importation of prescription drugs from licensed pharmacies in Canada, UK, Australia and New Zealand. It describes how the Maine Pharmacy Association President ordered drugs from an online Canadian pharmacy called Canada Drug Center and found the drugs to be substandard and contaminated. The law was struck down in 2015 because it compromised federal drug regulation. Attempts by other states to import drugs from foreign pharmacies similarly found poor oversight, unsafe drugs, and an inability to regulate foreign entities.
The document discusses the prescription drug price crisis in the United States. Drug prices have risen much faster than general inflation over the past decade, and millions of Americans cannot afford necessary medications as a result. The U.S. pays significantly higher prices for many drugs than other countries. Several policy solutions are proposed to lower drug costs, including allowing Medicare to negotiate drug prices, banning "pay-for-delay" deals between drug companies, and legalizing importation of lower-cost drugs from abroad. Advocacy groups are calling for stronger political action to enact reforms and lower what Americans pay for prescription medications.
Scott A. LaGanga, Executive Director Partnership for Safe Medicines (PSM) and Senior Vice President, Public Affairs -Advocacy at the Pharmaceutical Research and Manufacturers of America (PhRMA), opens PSM's Interchange 2014.
Illicit Trade in Counterfeit Medicine by Kristina M. Lybecker, The Colorado C...OECD Governance
Presentation made by Kristina M. Lybecker, The Colorado College at the 3rd meeting of the OECD Task Force on Charting Illicit Trade - OECD, Paris, 30-31 March 2015
For more information see http://www.oecd.org/gov/risk/charting-illicit-trade-third-task-force-meeting.htm
Counterfeit drugs pose a major global problem and public health risk. According to the World Health Organization, over half of counterfeit drug cases found no active ingredients, while others contained incorrect or dangerous ingredients. Developing countries are especially impacted, with up to 60% of reported counterfeit drugs. Counterfeiting undermines healthcare systems and can have deadly consequences. The document warns that weak drug regulation and an unsecured supply chain allow for counterfeits to proliferate. It advocates purchasing from authorized drug distributors only to help strengthen oversight of the pharmaceutical supply system.
Linda I. Marks, Senior Litigation Counsel, Consumer Protection Branch, U.S. Department of Justice speaks around criminal prosecutions of drug counterfeiters and diverters in the US.
BlockMedX is developing a blockchain solution to combat the opioid crisis by creating an immutable, fraud-proof prescription drug ledger. This ledger would authorize healthcare providers for prescription transactions using digital signatures, eliminate patient fraud and abuse, store prescription records across providers and state lines, and use machine learning to monitor for fraudulent activity in real-time. The solution aims to incentivize responsible behavior and reduce overdoses and healthcare costs associated with opioid abuse. There is currently no direct competition providing a real-time prescription monitoring database integrated into provider and pharmacy workflows.
OECD EUIPO Trade in Counterfeit Pharmaceutical ProductsOECD Governance
Presentation of key findings from the OECD EUIPO report "Trade in Counterfeit Pharmaceutical Products". For further details see https://oe.cd/pharmatrade
The document discusses counterfeit medicines, which the WHO defines as deliberately mislabeled drugs regarding identity and/or source. Counterfeits can include both branded and generic drugs with incorrect ingredients, dosages, or packaging. Medicines are targeted due to lax regulations in some countries, price differences globally, and the complexity of distribution systems. Counterfeits pose health risks as they provide ineffective treatment and can spread drug-resistant diseases. Stronger enforcement is needed across governments, industries, and distribution networks to prioritize combating counterfeit drugs.
Prescription Medicines - Costs In Context March 2019PhRMA
Discussions about costs are important. We recognize that many are struggling to access the medicine they need, and have important questions about their medicine costs. And we want to help find the answers.
Prescription Medicines - Costs in Context January 2019PhRMA
Discussions about costs are important. We recognize that many are struggling to access the medicine they need, and have important questions about their medicine costs. And we want to help find the answers.
The document discusses the benefits and risks of online pharmacies. It outlines the process of online distribution and notes that while e-pharmacies provide convenience, around 96% do not comply with laws. Benefits include lower prices, large selection and 24/7 access, but risks are self-medication without interaction, improper handling of medicines, and sale of controlled substances. Laws prohibit online pharmacies in India without a valid prescription. While e-pharmacies can increase access, proper rules and patient education are needed to ensure safety.
Libby Baney, Executive Director for the Alliance for Safe Online Pharmacies talks about the current state of rogue online pharmacies and efforts to curb them.
Prescription Medicines Costs in Context - June 2019PhRMA
We are in a new era of medicine where breakthrough science is transforming care with innovative treatment approaches and enabling us to more effectively treat chronic disease, the biggest cost driver.
June 19, 2013: This presentation to highlight the dangers of counterfeit drugs to Maine patients was given to the Bangor Dept. of Health Public Advisory committee
This presentation is designed to train patient advocates in the safety issues around counterfeit drugs: how counterfeits enter our supply chain and how patients can protect themselves.
A presentation by Tom T. Kubic, President and CEO, Pharmaceutical Security Institute and Treasurer, Partnership for Safe Medicines about the threat of imported counterfeit prescription drugs.
Counterfeit drugs: what a doctor should knowMark Davison
Short lecture to medical students on risks, prevalence and detection of fake medicines and protection of patient safety. Essential training for new doctors and pharmacists.
In this webinar I provide an overview of counterfeits in America, I talk about some myths of importation, and I teach patients and patient advocates some great tips for saving money safely.
Securing the Global Pharmaceutical Supply Chain against the Threat of Counter...Yasmin AbdelAziz
In 2012, counterfeit versions of the cancer drug
Avastin were found in 19 American treatment
centers. The impostor drug lacked the active
ingredient, rendering it virtually useless for
treatment purposes.
This document discusses Maine's experience with LD 171, a law passed in 2013 to legalize the importation of prescription drugs from licensed pharmacies in Canada, UK, Australia and New Zealand. It describes how the Maine Pharmacy Association President ordered drugs from an online Canadian pharmacy called Canada Drug Center and found the drugs to be substandard and contaminated. The law was struck down in 2015 because it compromised federal drug regulation. Attempts by other states to import drugs from foreign pharmacies similarly found poor oversight, unsafe drugs, and an inability to regulate foreign entities.
The document discusses the prescription drug price crisis in the United States. Drug prices have risen much faster than general inflation over the past decade, and millions of Americans cannot afford necessary medications as a result. The U.S. pays significantly higher prices for many drugs than other countries. Several policy solutions are proposed to lower drug costs, including allowing Medicare to negotiate drug prices, banning "pay-for-delay" deals between drug companies, and legalizing importation of lower-cost drugs from abroad. Advocacy groups are calling for stronger political action to enact reforms and lower what Americans pay for prescription medications.
Scott A. LaGanga, Executive Director Partnership for Safe Medicines (PSM) and Senior Vice President, Public Affairs -Advocacy at the Pharmaceutical Research and Manufacturers of America (PhRMA), opens PSM's Interchange 2014.
Illicit Trade in Counterfeit Medicine by Kristina M. Lybecker, The Colorado C...OECD Governance
Presentation made by Kristina M. Lybecker, The Colorado College at the 3rd meeting of the OECD Task Force on Charting Illicit Trade - OECD, Paris, 30-31 March 2015
For more information see http://www.oecd.org/gov/risk/charting-illicit-trade-third-task-force-meeting.htm
Counterfeit drugs pose a major global problem and public health risk. According to the World Health Organization, over half of counterfeit drug cases found no active ingredients, while others contained incorrect or dangerous ingredients. Developing countries are especially impacted, with up to 60% of reported counterfeit drugs. Counterfeiting undermines healthcare systems and can have deadly consequences. The document warns that weak drug regulation and an unsecured supply chain allow for counterfeits to proliferate. It advocates purchasing from authorized drug distributors only to help strengthen oversight of the pharmaceutical supply system.
Linda I. Marks, Senior Litigation Counsel, Consumer Protection Branch, U.S. Department of Justice speaks around criminal prosecutions of drug counterfeiters and diverters in the US.
BlockMedX is developing a blockchain solution to combat the opioid crisis by creating an immutable, fraud-proof prescription drug ledger. This ledger would authorize healthcare providers for prescription transactions using digital signatures, eliminate patient fraud and abuse, store prescription records across providers and state lines, and use machine learning to monitor for fraudulent activity in real-time. The solution aims to incentivize responsible behavior and reduce overdoses and healthcare costs associated with opioid abuse. There is currently no direct competition providing a real-time prescription monitoring database integrated into provider and pharmacy workflows.
OECD EUIPO Trade in Counterfeit Pharmaceutical ProductsOECD Governance
Presentation of key findings from the OECD EUIPO report "Trade in Counterfeit Pharmaceutical Products". For further details see https://oe.cd/pharmatrade
The document discusses counterfeit medicines, which the WHO defines as deliberately mislabeled drugs regarding identity and/or source. Counterfeits can include both branded and generic drugs with incorrect ingredients, dosages, or packaging. Medicines are targeted due to lax regulations in some countries, price differences globally, and the complexity of distribution systems. Counterfeits pose health risks as they provide ineffective treatment and can spread drug-resistant diseases. Stronger enforcement is needed across governments, industries, and distribution networks to prioritize combating counterfeit drugs.
Prescription Medicines - Costs In Context March 2019PhRMA
Discussions about costs are important. We recognize that many are struggling to access the medicine they need, and have important questions about their medicine costs. And we want to help find the answers.
Prescription Medicines - Costs in Context January 2019PhRMA
Discussions about costs are important. We recognize that many are struggling to access the medicine they need, and have important questions about their medicine costs. And we want to help find the answers.
The document discusses the benefits and risks of online pharmacies. It outlines the process of online distribution and notes that while e-pharmacies provide convenience, around 96% do not comply with laws. Benefits include lower prices, large selection and 24/7 access, but risks are self-medication without interaction, improper handling of medicines, and sale of controlled substances. Laws prohibit online pharmacies in India without a valid prescription. While e-pharmacies can increase access, proper rules and patient education are needed to ensure safety.
Libby Baney, Executive Director for the Alliance for Safe Online Pharmacies talks about the current state of rogue online pharmacies and efforts to curb them.
Prescription Medicines Costs in Context - June 2019PhRMA
We are in a new era of medicine where breakthrough science is transforming care with innovative treatment approaches and enabling us to more effectively treat chronic disease, the biggest cost driver.
June 19, 2013: This presentation to highlight the dangers of counterfeit drugs to Maine patients was given to the Bangor Dept. of Health Public Advisory committee
This presentation is designed to train patient advocates in the safety issues around counterfeit drugs: how counterfeits enter our supply chain and how patients can protect themselves.
This document summarizes a panel discussion on issues related to fake online pharmacies. The panelists included pharmacists, law enforcement agents, and policy experts. They discussed how online pharmacies are difficult to regulate due to their ability to operate across state and international lines. While organizations like the FDA and NABP have programs to verify legitimate online pharmacies, illicit sites still proliferate using search engines, social media, and other online marketing techniques. Research presented found that consumers have difficulty identifying unsafe pharmacy websites and are willing to purchase medicines from illegal online pharmacies without prescriptions, including drugs that require close medical supervision.
The document summarizes key points from a presentation by Daniel Bennett, CEO of Yellow Brand Protection, on anti-counterfeiting efforts in the pharmaceutical industry. It discusses the growth of the global pharmaceutical market and issues around counterfeit and substandard drugs. It also examines the evolution of online pharmaceutical sales channels like webstores, social media, and online marketplaces, noting challenges in regulating these channels, especially in China as it lifts its ban on online drug sales.
The document discusses e-pharmacy, which refers to online platforms for purchasing medicines. It outlines the definition, history, key players, types, components, regulations, and future of e-pharmacy in India. E-pharmacies allow consumers to purchase medicines online without visiting brick-and-mortar stores. While convenient for consumers, e-pharmacy also raises issues around safety, accountability and adherence to pharmacy laws and regulations. The government of India is working to develop policies to regulate e-pharmacies and ensure public health standards are met.
The document discusses regulations around online pharmacy services. It notes that while online pharmacies provide convenience, regulatory authorities have concerns about safety due to illegitimate sites that dispense drugs without prescriptions or provide low quality drugs. The document outlines various regulatory approaches taken around the world to address this, including laws, international agreements, accreditation programs, and restrictions on online sales of controlled substances. The goal of regulations is to protect public health by distinguishing between legal and illegal online pharmacies.
Leveraging Public-Private Partnerships in Surveillance, Enforcement and Preve...Global Risk Forum GRFDavos
Global counterfeit drugs sold online pose a major public health risk. Unregulated internet pharmacies sell counterfeit medicines to unsuspecting consumers around the world, threatening patient safety. Current enforcement efforts are inadequate, as illicit online drug sales can still be easily found. A coordinated, multi-sector approach is needed involving public-private partnerships between law enforcement, regulatory agencies, internet and payment companies, and others. Through active surveillance of online drug sales, information sharing, and prevention efforts, partnerships can help curb this growing global health threat.
This document discusses the issue of online drug sales via the internet. It notes that prescription drugs can now be easily purchased online, which challenges drug enforcement agencies. The U.S. House held hearings to understand this problem. Some online pharmacies illegally distribute addictive drugs. Trafficking in illegal prescription drugs now equals or exceeds sales of drugs like heroin and cocaine. Online drug sites attract customers with lower prices from countries like Canada and countries in Europe and elsewhere. Efforts are being made to identify and crack down on illegal online pharmacies.
Fighting black market and counterfeit drugs in America endangers patients. Any break in the regulated, closed supply chain - whether by patients buying drugs online, or medical professionals purchasing from unlicensed distributors - puts lives at risk. Counterfeit or improperly handled treatments for conditions like HIV/AIDS, osteoporosis, kidney disease, and diabetes can be ineffective or even life-threatening when patients' health depends on properly manufactured and stored medicine. Protecting the supply chain is crucial to patient safety.
This document discusses ethical issues related to pharmaceutical marketing and promotion. It notes that most physicians have relationships with the pharmaceutical industry, including receiving gifts and drug samples. It also outlines WHO ethical criteria for drug promotion, including that claims should not contain misleading statements to induce unjustified drug use. The document advocates establishing national frameworks to promote governance and prevent corruption related to drug promotion and procurement.
This document discusses ethical issues related to pharmaceutical marketing and promotion. It notes that most physicians have relationships with the pharmaceutical industry, including receiving gifts and drug samples. It also outlines WHO ethical criteria for drug promotion, including that claims should not contain misleading statements to induce unjustified drug use. The document advocates establishing national frameworks to promote governance and prevent corruption related to drug promotion and procurement.
This document discusses counterfeit medicines and measures to combat them. It defines counterfeit medicines according to WHO as those deliberately mislabeled regarding identity and/or source. The most common types of counterfeits are those without active ingredients or with incorrect quantities. Counterfeiting is prevalent in developing countries and online pharmacies. It poses dangers like treatment failure, toxicity, and drug resistance. Detection methods include chemical kits, barcodes, and Raman spectroscopy. Measures to combat counterfeits involve legislation, regulation, international cooperation, and awareness campaigns. Pharmacists play a role in preventing counterfeits from entering the supply chain.
For 20 years, United States politicians have been interested in fighting their high drug prices by bulk importing prescription drugs from Canada.
Recently, the politically-appointed head of the US Health Department has said they are proposing new rules to make allowances for this practice. The State of Florida, with a population of 25 million, has also passed new legislature and published a 40-page plan, and the Florida Governor has met with the President and the Health Secretary to move forward. This creates a clear and present risk to the supply of medicines for Canadians.
Presented by John Adams, Board Chair, Best Medicines Coalition and Co-Founder, President & CEO, Canadian PKU and Allied Disorders, this webinar offers an opportunity to learn more about this potential threat and how to approach the new Canadian government and urge necessary action before access to prescription drugs is potentially compromised.
This document discusses e-pharmacies and the online pharmacy market in India. It provides background on e-pharmacies, noting that they allow consumers to purchase medicines online without visiting brick-and-mortar stores. A survey of 150 respondents found that most were unaware of online pharmacy apps, though the 17 who had used them were generally satisfied with services like discounts and on-time delivery. While the online market is growing, regulations for e-pharmacies in India are still developing to properly address issues like potential counterfeit drugs and promoting self-medication. Overall the online pharmacy sector remains in its early stages but may significantly impact retail if regulated appropriately alongside technological advances.
High Cost of Prescription Drugs - What can we do about it?Vincent Rajkumar
This document discusses the high costs of cancer drugs and potential solutions. It notes that the average cost of new cancer drugs approved in 2014 was over $120,000 per year, creating financial hardship. It argues that drug companies' justifications for high prices, such as research costs, are overstated. The document proposes several approaches to control drug costs, including value-based pricing, importing drugs, increasing competition through generics, developing treatment guidelines, and allowing Medicare to negotiate prices. The goal is to balance drug access with pharmaceutical industry innovation and profits.
This document discusses why importing prescription drugs from Canada is not a viable solution to high drug costs in the US. It notes that previous state-level importation programs failed due to lack of savings and inability to adequately regulate foreign pharmacies. Proper testing of imported drugs is very expensive and would consume any savings. There are also safety concerns, as importation would undermine track-and-trace systems and Canada's drug supply is already limited. Law enforcement experts warn that importation could exacerbate the opioid crisis and organized crime may exploit regulatory loopholes. The document argues policymakers should focus on real solutions rather than unrealistic importation proposals.
This presentation by Pradeep Mehta was made at the 2014 Global Forum on Competition (27-28 February) during the session on competition issues in the distribution of pharmaceuticals. Find out more at http://www.oecd.org/competition/globalforum
IFPMA-TFDA Workshop on Couterfeit Medicines
‘Integrated Approach Against Fake Medicines’
Session 2: Supply Chain Integrity
On 6th February 2015
At Taipei International Convention Center
Taipei, Taiwan
Similar to Online Access to Safe and Affordable Medication: Applying human rights law to cyber rule-making and Internet governance (20)
Jennifer Schaus and Associates hosts a complimentary webinar series on The FAR in 2024. Join the webinars on Wednesdays and Fridays at noon, eastern.
Recordings are on YouTube and the company website.
https://www.youtube.com/@jenniferschaus/videos
Jennifer Schaus and Associates hosts a complimentary webinar series on The FAR in 2024. Join the webinars on Wednesdays and Fridays at noon, eastern.
Recordings are on YouTube and the company website.
https://www.youtube.com/@jenniferschaus/videos
Contributi dei parlamentari del PD - Contributi L. 3/2019Partito democratico
DI SEGUITO SONO PUBBLICATI, AI SENSI DELL'ART. 11 DELLA LEGGE N. 3/2019, GLI IMPORTI RICEVUTI DALL'ENTRATA IN VIGORE DELLA SUDDETTA NORMA (31/01/2019) E FINO AL MESE SOLARE ANTECEDENTE QUELLO DELLA PUBBLICAZIONE SUL PRESENTE SITO
This report explores the significance of border towns and spaces for strengthening responses to young people on the move. In particular it explores the linkages of young people to local service centres with the aim of further developing service, protection, and support strategies for migrant children in border areas across the region. The report is based on a small-scale fieldwork study in the border towns of Chipata and Katete in Zambia conducted in July 2023. Border towns and spaces provide a rich source of information about issues related to the informal or irregular movement of young people across borders, including smuggling and trafficking. They can help build a picture of the nature and scope of the type of movement young migrants undertake and also the forms of protection available to them. Border towns and spaces also provide a lens through which we can better understand the vulnerabilities of young people on the move and, critically, the strategies they use to navigate challenges and access support.
The findings in this report highlight some of the key factors shaping the experiences and vulnerabilities of young people on the move – particularly their proximity to border spaces and how this affects the risks that they face. The report describes strategies that young people on the move employ to remain below the radar of visibility to state and non-state actors due to fear of arrest, detention, and deportation while also trying to keep themselves safe and access support in border towns. These strategies of (in)visibility provide a way to protect themselves yet at the same time also heighten some of the risks young people face as their vulnerabilities are not always recognised by those who could offer support.
In this report we show that the realities and challenges of life and migration in this region and in Zambia need to be better understood for support to be strengthened and tuned to meet the specific needs of young people on the move. This includes understanding the role of state and non-state stakeholders, the impact of laws and policies and, critically, the experiences of the young people themselves. We provide recommendations for immediate action, recommendations for programming to support young people on the move in the two towns that would reduce risk for young people in this area, and recommendations for longer term policy advocacy.
Indira awas yojana housing scheme renamed as PMAYnarinav14
Indira Awas Yojana (IAY) played a significant role in addressing rural housing needs in India. It emerged as a comprehensive program for affordable housing solutions in rural areas, predating the government’s broader focus on mass housing initiatives.
Combined Illegal, Unregulated and Unreported (IUU) Vessel List.Christina Parmionova
The best available, up-to-date information on all fishing and related vessels that appear on the illegal, unregulated, and unreported (IUU) fishing vessel lists published by Regional Fisheries Management Organisations (RFMOs) and related organisations. The aim of the site is to improve the effectiveness of the original IUU lists as a tool for a wide variety of stakeholders to better understand and combat illegal fishing and broader fisheries crime.
To date, the following regional organisations maintain or share lists of vessels that have been found to carry out or support IUU fishing within their own or adjacent convention areas and/or species of competence:
Commission for the Conservation of Antarctic Marine Living Resources (CCAMLR)
Commission for the Conservation of Southern Bluefin Tuna (CCSBT)
General Fisheries Commission for the Mediterranean (GFCM)
Inter-American Tropical Tuna Commission (IATTC)
International Commission for the Conservation of Atlantic Tunas (ICCAT)
Indian Ocean Tuna Commission (IOTC)
Northwest Atlantic Fisheries Organisation (NAFO)
North East Atlantic Fisheries Commission (NEAFC)
North Pacific Fisheries Commission (NPFC)
South East Atlantic Fisheries Organisation (SEAFO)
South Pacific Regional Fisheries Management Organisation (SPRFMO)
Southern Indian Ocean Fisheries Agreement (SIOFA)
Western and Central Pacific Fisheries Commission (WCPFC)
The Combined IUU Fishing Vessel List merges all these sources into one list that provides a single reference point to identify whether a vessel is currently IUU listed. Vessels that have been IUU listed in the past and subsequently delisted (for example because of a change in ownership, or because the vessel is no longer in service) are also retained on the site, so that the site contains a full historic record of IUU listed fishing vessels.
Unlike the IUU lists published on individual RFMO websites, which may update vessel details infrequently or not at all, the Combined IUU Fishing Vessel List is kept up to date with the best available information regarding changes to vessel identity, flag state, ownership, location, and operations.
Online Access to Safe and Affordable Medication: Applying human rights law to cyber rule-making and Internet governance
1. Online Access to Safe and Affordable Medication
Applying human rights law to cyber rule-making and Internet
governance
2. Access to Medicines:
a Global Public Health Crisis
• Two billion people can’t access essential medication.1
• According to the UN High Level Panel on Access to Medicine, prices are a barrier to
essential medicines not just in poor and middle income countries, but in rich
countries too.2
• Forty-five million Americans did not fill a prescription due to cost in 2016.3
• President of Medicines Sans Frontier: “There is a life attached to every calculation of
supply and demand for medicines.”4
3. Online Access: The Bottom Line
• Internet users are benefiting from online access to safe and affordable medications.5
• The pharmaceutical industry views Internet access as a threat and disruptive to its
profit model because consumers are paying less than the drug companies intended
for them to pay.6
• According to the UN Human Rights Council, access to affordable medication is a
human right.7
• As the Internet community seeks to infuse the principles of international human
rights law into the discourse and practice of Internet governance it should help
maintain the widest possible online access to safe and affordable medication.6
4. What is online access to affordable medication?
• Obtaining a medication from another country at a lower cost than is possible from a
local pharmacy ordering it online.
• Millions of Americans who can’t afford medication having an opportunity to do so
because of the Internet.8
• In London, people at risk for HIV are able to obtain affordable generic Truvada online
from India to protect themselves from HIV.9
• Cancer patients in China obtaining medication over the Internet.10
5. U.S. and Access to Healthcare
• 45 million Americans did not fill prescription in 2016 because of cost.11
• 27 million American adults don’t have insurance.12
• About 31 million are underinsured.12
Did not fill
prescription or
skipped doses AUS CAN FR GER NET NZ NOR SWE SWIZ UK US
2016 6% 10% 4% 3% 4% 6% 3% 6% 9% 2% 18%
6. Online Drug Price Comparisons
www.pharmacychecker.com
Drug U.S. Price1 Canadian Price2 /
(Savings)
International Price3 /
(Savings)
Advair Diskus
Condition: Asthma and COPD
$977.97 $341.07 (65.12%) $98.99 (89.88%)
Zetia4
Condition: High Cholesterol
$835.70 $227.49 (72.78%) $155.99 (81.33%)
Januvia
Condition: Type-2 Diabetes
$1,061.44 $350.67 (66.96%) $90.62 (91.46%)
Daraprim
Condition: Toxoplasmosis
$4,6043.4 N/A $97.20 (99.79%)
Epipen Autoinjector
Condition: Asthma / Allergic
$630.96 $225.42 (64.27%) $171.99 (72.74%)
7. Quick History of Online Pharmacy for Americans
• An extension of mail-order pharmacy, which dates back to the 1890s.
• In the U.S. about 30% of domestic retail pharmacy is by mail order.13
• International online pharmacy started in the late 1990s, an outgrowth of e-
commerce happening in all sector.
8. Bus Trips to Canada
“I will never forget the look on the faces of those
women who were struggling for their lives when
they bought breast cancer medicine at 10 percent
of the cost they were paying in the state of
Vermont. The drug was Tamoxifen, a widely
prescribed drug for those people who are
struggling with breast cancer.14”
9. The Internet Expands Access
• The Internet enabled more Americans to buy lower cost medications from Canada,
whereas before, access was mostly for border state residents.
• Government survey data show about four million Americans import medication for
personal use each year. [U.S. Centers for Disease Control and Prevention].16
10. So What’s the Problem?
• Regulatory Restrictions to Importing Affordable Medication
• Big Pharma/Pharmacy Doesn’t Like It!
• Rogue Online Pharmacies are dangerous.
11. U.S. Regulatory Barriers to Affordable Medication
• It’s technically illegal to import medication for personal use.
• FDA and Pharma say it’s a safety issue but the industry hypes the threat to Orwellian
heights of propaganda.
• The illegality is “technical” because individuals have never been prosecuted for
importing personal use quantities of medication.17
12. Big Pharma/Pharmacy Doesn’t Like It!
• Multinational pharmaceutical companies rely on the U.S. market for their
phenomenal profits.
• U.S. pharmacies don’t want the competition.
• Importation laws don’t stop Americans from personal importation.
13. Scare People from Ordering Affordable Medications
• PhRMA hired Edelman Public Relations to form focus groups, which found that fear
would work better than the yellow light of the law.18
• Wall Street Journal (2003): [Edelman’s] “report recommends that the U.S. industry
question the safety and effectiveness of medicines procured elsewhere.” 18
• Strategy: Conflate international online pharmacies with online counterfeit drug
sellers.
15. Ecosystem of Pharma-allied and/or funded groups
• Partnership for Safe Medicines (PhRMA)
• National Association of Boards of Pharmacy (Funding by drug companies, represents
U.S. pharmacy boards)
• LegitScript (Contract with FDA, allied with Alliance for Safe Online Pharmacies)
• Alliance for Safe Online Pharmacies (Drug companies, U.S. chain pharmacies)
• Center for Safe Internet Pharmacies (Large Internet companies working with
LegitScript and Alliance Safe Online Pharmacies)
16. Actions to Curtail Online Access
1. NABP’s ICANN gTLD - .Pharmacy campaign, require VIPPS or LegitScript.
2. Google and Bing won’t allow Safe international online pharmacies to advertise.
3. VISA/MasterCard require LegitScript approval
4. Some registrars look to LegitScript and the NABP for White Lists.
5. BING has placed filters on its organic search results warning against websites that
the FDA has sent a letter to, which it refers to as “fake online pharmacies.”
17. Educating the Internet Community
• The Internet community needs to be able to distinguish safe international online
pharmacies from rogue online pharmacies.
• A safe online pharmacy requires a valid prescription, facilitates the processing of
orders sent by mail from lawfully operating and licensed pharmacies, protects the
privacy of patients, and makes sure customers have access to consult with a licensed
pharmacist.
• A rogue online pharmacy intentionally sells counterfeit or adulterated medication;
real medication but without requiring a prescription and/or not under the
supervision of licensed personnel.
18. Online Pharmacy Credentialing Programs
• PharmacyChecker, 2002 (Independently funded, revenue comes from verification
program and pharmacy/price listing fees)
• NABP and VIPPS, 1999 (Funded by program fees, U.S. state pharmacy boards, and
related programs, and drug companies)
• Canadian International Pharmacy Association , 2002 (Funded by international online
pharmacies)
• LegitScript, 2007 (Revenue from government contracts with U.S. FDA, Japan, large
Internet companies, other businesses focused on compliance issues)
• European Union (Funded by EU taxpayers)
19. PharmacyChecker Verification
What do we check/verify?
• pharmacy licenses
• prescription requirements
• marketing claims
• privacy protocols
• contact information
• transparency of pharmacy sources
• pharmacist consultation policies
• Written agreements among online pharmacies and filling pharmacies
• Inspections
• Mystery shopping
• Reverifications
20. Medicines Access Advocacy in the Internet Ecosystem
• Create a Code of Ethics or Statement of Principles for the online sale of medication.
• Registrars to refuse website takedown requests by NABP, LegitScript or regulators
without a court order, especially credentialed websites.
• Guide banks and businesses to provide service to websites processing prescription
orders filled by lawfully operating pharmacies.
• To help engage with ICANN to continue resisting pressure from the pharmaceutical
industry.